Targeting cereblon in hematologic malignancies

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F23%3A00013429" target="_blank" >RIV/00023736:_____/23:00013429 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1016/j.blre.2022.100994" target="_blank" >https://doi.org/10.1016/j.blre.2022.100994</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.blre.2022.100994" target="_blank" >10.1016/j.blre.2022.100994</a>

Result language
angličtina
Original language name
Targeting cereblon in hematologic malignancies
Original language description
The protein cereblon (CRBN) is a substrate receptor of the cullin 4-really interesting new gene (RING) E3 ubiquitin ligase complex CRL4CRBN. Targeting CRBN mediates selective protein ubiquitination and subsequent degradation via the proteasome. This review describes novel thalidomide analogs, immunomodulatory drugs, also known as CRBN E3 ubiquitin ligase modulators or molecular glues (avadomide, iberdomide, CC-885, CC-90009, BTX-1188, CC-92480, CC-99282, CFT7455, and CC-91633), and CRBN-based proteolysis targeting chimeras (PROTACs) with increased efficacy and potent activity for application in hematologic malignancies.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)